Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2019;2020:2020. https://doi.org/10.1101/2020.02.06.20020974. Accessed 20 Feb 2020.

Xu KJ,Cai HL,Shen YH,et a1. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao (Yi Xue Ban). 2020. https://kns.cnki.net/kcms/detail/33.1248.R.20200222.1417.002.html. Accessed 3 Mar 2020 (in Chinese).

General Office of the National Health Committee of China, China Traditional Chinese Medicine Administration Office. Diagnosis and treatment plan of novel coronavirus pneumonia (seventh trial edition). 2020. http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95.shtml. Accessed 11 Mar 2020.

Jennifer RT, Marcus JK, Cameron PS, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.

Fei ZY, Dong H, Qian QJ, et al. Analysis of pathogens and risk factors for death in elderly patients with severe pneumonia. Zhong Hua Yi Yuan Gan Ran Xue Za Zhi. 2019;29(3):380–3 (in Chinese).

Ma YP, Yan YH, Sun XD, et al. Correlation between inflammatory factor expression level in severe pneumococcal alveolar lavage fluid and prognosis. Zhong Hua Yi Yuan Gan Ran Xue Za Zhi. 2019;29(7):1007–10 (in Chinese).

Zhang JW, Hu X, Jin PF. Cytokine storm induced by SARS-CoV-2 and the drug therapy. Zhongguo Yao Xue Za Zhi. 2020. https://kns.cnki.net/kcms/detail/11.2162.R.20200225.1052.002.html. Accessed 9 Feb 2020 (in Chinese).

Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25(1 Pt 2):1216–17.

De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203–7.

Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–79.

Zhang YL, Jiang CY. Cytokine storm in ARDS. Sheng Ming Ke Xue. 2015;5:554–7 (in Chinese).

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2019;2020:2020. https://doi.org/10.1001/jama.2020.1585. Accessed 15 Feb 2020.

Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhong Hua Jie He He Hu Xi Za Zhi. 2019;2020:2020. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0005. Accessed 15 Feb 2020 (in Chinese) .

Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2019;2020:2020. https://doi.org/10.1101/2020.02.10.20021832. Accessed 20 Feb 2020.

Jing L, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. MedRxiv. 2020. https://doi.org/10.1101/2020.02.16.20023671. Accessed 3 Mar 2020.

Zhai H, Liu YW, Wang Y, et al. The pathogen distribution and its influence on inflammatory factors in old patients with heart failure complicated with pulmonary infection. Tianjin Yi Yao. 2018;46(9):952–5 (in Chinese).

Zhou YG, Fu BQ, Zheng XH, et al. Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16 + monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv. 2020. https://doi.org/10.1101/2020.02.12.945576. Accessed 20 Mar 2020.

Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–70.

Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–31.

Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–89.

Braun GS, Nagayama Y, Maruta Y, et al. IL-6 trans-signaling drives murine crescentic GN. Am Soc Nephrol. 2016;27(1):132–42.

Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–84.

Zegeye MM, Madelene L, Knut F, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal. 2018;16(1):55.

Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–48.

Rose-John S. The soluble Interleukin 6 receptor: advanced therapeutic options in inflammation. Clin Pharmacol Ther. 2017;102(4):591–8.

The first affiliated hospital of university of science and technology. The efficacy and safety of tocilizumab in the treatment of novel coronavirus pneumonia: a multi-center, randomized, double-blinded trial. 2020. https://www.chictr.org.cn/showproj.aspx?proj=49409. Accessed 22 Feb 2020.

Genentech. Genentech announces FDA approval of clinical trial for actemra to treat hospitalized patients with severe COVID-19 Pneumonia;. 2020. https://www.gene.com/media/press-releases/14843/2020-03-23/genentech-announces-fda-approval-of-clin. Accessed 27 Mar 2020.

Xu XL, Han MF, Li TT, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv. 2020. http://www.chinaxiv.org/abs/202003.00026. Accessed 20 Mar 2020.

The U.S. Food and Drug Administration. Information for ACTEMRA® (tocilizumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf. Accessed 15 Feb 2020.

Ferfar Y, Mirault T, Desbois AC, et al. Biotherapies in large vessel vasculitis. Autoimmun Rev. 2016;15(6):544–51.

Samson M, Devilliers H, Ly KH, et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: a prospective study. Eur J Intern Med. 2018;57:96–104.

Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan(the TAKT study). Ann Rheum Dis. 2018;77(3):348–54.

Liao H, Pan LL, Du J, et al. Efficacy and safety of tocilizumab in patients with Takayasu arteritis. Zhong Hua Nei Ke Za Zhi. 2019;58(6):444–8 (in Chinese).